Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of lovastatin cas 75330-75-5 in China. Welcome to wholesale bulk high quality lovastatin cas 75330-75-5 for sale here from our factory. Good service and reasonable price are available.
Lovastatin is an organic compound with the chemical formula of C24H36O5 and CAS 75330-75-5. It is a lipid-lowering drug, which can reduce the synthesis of cholesterol and increase the synthesis of low-density lipoprotein receptor. Its main role is in the liver. As a result, the level of blood cholesterol and low-density lipoprotein cholesterol is reduced, which has a role in the prevention and treatment of atherosclerosis and coronary heart disease. It is a white to off white crystalline powder, odorless, tasteless, and slightly hygroscopic. It has a certain solubility in organic solvents such as ethanol, acetone, ethyl acetate, or acetonitrile. It is easily soluble in chloroform and soluble in ethanol at a concentration of 9.80-10.20 mg/mL (clear, colorless to light yellow). The lipid-lowering effect is mainly due to specific functional groups in its structure, which can competitively inhibit the activity of HMG CoA reductase, thereby reducing cholesterol synthesis. Its partial structure, 3,5-dihydroxyheptanoic acid, is similar to that of HMG CoA and has strong inhibitory affinity, thus effectively blocking the biosynthesis pathway of cholesterol.
|
|
|
|
Chemical Formula |
C24H36O5 |
|
Exact Mass |
404 |
|
Molecular Weight |
405 |
|
m/z |
404 (100.0%), 405 (26.0%), 406 (2.7%), 406 (1.0%) |
|
Elemental Analysis |
C, 71.26; H, 8.97; O, 19.77 |
Lovastatin, as an important pharmaceutical ingredient, is commonly synthesized through the following methods:
1. Microbial fermentation method
This is the method by which lovastati was initially discovered and prepared. In the 1970s, Japanese scientists first isolated the drug Mevastatin, which has the ability to inhibit HMG CoA reductase activity, from the metabolites of Penicillium citrinum. Subsequently, scientists obtained lovastati through the fermentation broth of other fungi. This method utilizes the natural metabolic processes of microorganisms to produce target compounds and has advantages such as low production costs and environmental friendliness.
2. Semi synthetic method
The semi synthetic method uses lovastati produced by microbial fermentation as the raw material, and through a series of chemical reactions, obtains its derivatives or other related drugs. For example, simvastatin is an HMG CoA reductase inhibitor obtained by semi synthesis of lovastati. This method can fully utilize the structural characteristics of natural products and enhance the activity, stability, or pharmacokinetic properties of drugs through chemical modification.
3. Total synthesis method
Although the total synthesis route of lovastati itself may be relatively complex and costly, the total synthesis method provides great flexibility and creativity for medicinal chemists. By designing a reasonable synthesis route, compounds with complex structures that are difficult to obtain through fermentation or semi synthetic methods can be prepared. However, for lovastati, due to its abundant natural sources and easy availability through microbial fermentation, total synthesis may not be common in practical applications.
The common methods for preparing lovastati mainly include microbial fermentation, semi synthesis, and total synthesis. Among them, microbial fermentation has become the main method for producing lovastati due to its advantages of low cost and environmental friendliness; The semi synthetic method provides an important pathway for the preparation of derivatives of lovastati; The total synthesis method provides more possibilities and choices for medicinal chemists. It should be noted that with the continuous development of science and technology, new synthesis methods and processes continue to emerge, and the preparation technology of lovastati will also continue to improve and perfect in the future.
Lovastatin is a lipid-lowering drug that primarily exerts its therapeutic effect by inhibiting endogenous cholesterol synthesis. Its main functions include:
1. Lowering blood lipids:
It can competitively inhibit the rate limiting enzyme hydroxymethylglutaryl CoA reductase (HMGCoA) in the cholesterol synthesis process in the body, reducing cholesterol synthesis and increasing low-density lipoprotein receptor synthesis, thereby reducing total cholesterol and low-density lipoprotein cholesterol levels in the serum.
2. Prevention and treatment of atherosclerosis and coronary heart disease:
Because it can reduce blood lipids, it helps to stabilize the plaque on the vascular wall, delay the progression of atherosclerosis, and thus plays an important role in the prevention and treatment of ischemic cardiovascular and cerebrovascular diseases caused by atherosclerosis, such as coronary heart disease, carotid atherosclerosis, and cerebral infarction.
3. Reduce serum triglyceride levels and increase blood high-density lipoprotein levels:
In addition to lowering cholesterol, it can also reduce serum triglyceride levels and increase blood high-density lipoprotein (HDLC) levels, which is beneficial for cardiovascular health.
Lovastatin works by inhibiting endogenous cholesterol synthesis, reducing the synthesis of very low-density lipoprotein cholesterol, promoting the breakdown of low-density lipoprotein, inhibiting hepatic fatty acid synthesis, and inhibiting intracellular low-density lipoprotein oxidative modification. This drug can be used for the treatment of diseases such as hypercholesterolemia and mixed hyperlipidemia.
1. Inhibit endogenous cholesterol synthesis
By competitively inhibiting hydroxyglutaryl-CoA reductase, the conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonic acid is reduced, thereby inhibiting endogenous cholesterol synthesis. This drug can effectively reduce serum total cholesterol and low-density lipoprotein cholesterol levels, and is suitable for the treatment of hypercholesterolemia and mixed hyperlipidemia.
2. Reduce the synthesis of very low-density lipoprotein cholesterol
It can increase the number and activity of LDL receptors on the cell surface, accelerate the degradation of lipid particles in endosomes, and thereby reduce the content of very low-density lipoprotein cholesterol in the blood. Patients can use this product for conditioning according to medical advice, but attention should be paid to monitoring liver function to avoid discomfort.
3. Promote the breakdown of low-density lipoprotein
It can enhance LDL receptor mediated LDL uptake and catabolism on the cell surface, helping to reduce the concentration of low-density lipoprotein cholesterol in plasma. For patients with elevated low-density lipoprotein, doctors may consider prescribing this medication to improve blood lipid levels. During medication, regular checks should be conducted on indicators such as blood lipids and liver function.
4. Inhibit hepatic fatty acid synthesis
It can downregulate the expression of steroid regulatory element binding transcription factor SREBP-1c, thereby reducing the synthesis of fatty acids in the liver. SREBP-1c is a key molecule regulating fatty acid synthesis, and its decreased expression leads to a reduction in fatty acid synthesis, which is beneficial for the liver. Therefore, it can be used to treat hyperlipidemia, atherosclerosis and other diseases clinically.
5. Inhibit intracellular low-density lipoprotein oxidation modification
Has antioxidant properties, can prevent oxidative modification of low-density lipoprotein in cells, delay its oxidative modification process, thereby preventing or alleviating related pathophysiological reactions. When targeting specific populations, it is necessary to adjust the dosage or take special measures to ensure safety and effectiveness. For example, elderly patients or those with renal insufficiency should be cautious when using it, and their renal function should be regularly evaluated.
Hypercholesterolemia will form atherosclerotic plaques, and then lead to atherosclerosis, coronary heart disease and other diseases, and even a series of cardiovascular and cerebrovascular diseases such as myocardial infarction and cerebral infarction. The increase in cholesterol levels in the blood, especially low-density lipoprotein cholesterol (LDL-c) levels, increases the risk of cardiovascular disease in the human body.
The biosynthesis of human cholesterol is a nearly 30 step process, in which HMG CoA is the rate limiting enzyme that controls the rate of cholesterol synthesis. By inhibiting HMG CoA reductase, cholesterol biosynthesis can be prevented, thereby reducing cholesterol levels in the human body.
Japanese scientist Professor Endo Akira successfully isolated the potent HMG CoA reductase competitive inhibitor mevalostatin from Aspergillus niger. However, the clinical trial of mevalonate was terminated due to its toxicity to intestinal lymphoma.
Alfred Alberts and his team from Merck discovered an effective HMG CoA reductase inhibitor from Aspergillus niger fermentation broth in soil and named it lovastati.
Zhang Endo obtained an HMG CoA reductase inhibitor from Monascus purpureus and named it Monacolin K. It is actually the same compound as lovastati. After more than 7 years of clinical trials, the safety and efficacy of lovastati have been comprehensively evaluated.
Merck's application for lovastati was approved by the US Food and Drug Administration (FDA), becoming the first commercial statin drug. Subsequently, a series of "statins" were introduced, providing various effective drugs for cholesterol regulation.
Statins are known as the "penicillin of lipid-lowering", and their discovery and new understanding of cardiovascular disease are one of the most important scientific research achievements in the biomedical field of the 20th century.
The invention of lovastati is a long process from basic research discovery to drug development. Dr. Earl Rachel Statman, a biochemist at the National Institutes of Health (NIH) in the United States, is the giant who laid the foundation for this cause that benefits human health. The New York Times published an obituary on July 3, 2018, stating that American biochemist Alfred Alberts (1931-2018), the inventor of the first cholesterol targeted drug, passed away on June 16 in Colorado due to heart disease at the age of 87. Alberts' life was so unique: he received doctoral training but never obtained a doctoral degree; He persisted for over thirty years and invented the first cholesterol lowering drug, lovastati; He was unwilling to devote himself to writing medical papers, and his name was not even known to his peers, but when the doctors who saved him learned of his enormous contributions, they gave him rock star like treatment... After Alberts passed away, Dr. Roy Vagelos, an 89 year old member of the American Academy of Sciences and former president of Merck, said in an interview with The New York Times: Alberts is my right-hand man, and we have known each other for over 60 years, as close as brothers. In many of his papers, Vajeros listed Alberts as a co-author, but regarding the attribution of honor to lovastati, Vajeros believes that "lovastatin was discovered by Alberts
Market demand growth
Hypercholesterolemia is a common disease that affects a large number of people worldwide. With the improvement of people's living standards, unhealthy lifestyles and eating habits become more and more common, leading to a rising incidence rate of hypercholesterolemia. This provides a huge market demand for such lipid-lowering drugs. Cardiovascular disease is one of the major health problems worldwide, and its occurrence is closely related to high cholesterol. It can effectively reduce the risk of cardiovascular disease by lowering the levels of low-density lipoprotein cholesterol (LDL-C) in the blood. Therefore, it has important application value in the prevention and treatment of cardiovascular diseases.
Significant drug efficacy
It is a hydroxymethylglutarate monoacyl CoA (HMG CoA) reductase inhibitor that inhibits the rate limiting enzyme HMG CoA reductase in cholesterol synthesis, blocking endogenous cholesterol synthesis and reducing intracellular cholesterol levels. This mechanism makes lovastatin significantly effective in lowering blood lipids. In addition to lowering blood lipids, it can also improve the function of endothelial cells, promote the production of nitric oxide synthase (eNOS), and increase the synthesis and release of nitric oxide (NO). This helps maintain normal pulmonary vascular tension, reverse hypoxia induced pulmonary vasoconstriction and vascular remodeling. It also has anti-inflammatory and anti proliferative effects, which can inhibit the proliferation of renal mesangial cells and the secretion of extracellular matrix, thereby achieving the goal of reducing glomerulosclerosis. These additional pharmacological effects further enhance their value in clinical applications.
Market competition and opportunities
Despite the broad market prospects, market competition is also very fierce. Many pharmaceutical companies are producing similar blood lipid regulators, which requires their manufacturing companies to constantly innovate in product quality, price, marketing strategies, and other aspects to maintain a competitive advantage. Faced with fierce market competition, its manufacturing enterprises can respond to challenges by strengthening research and development, improving product quality, and expanding sales channels. Meanwhile, with the increasing awareness of health and the continuous advancement of medical technology, the market demand for such lipid-lowering drugs will continue to grow, bringing development opportunities for enterprises.
Future Development Trends
With the continuous advancement of science and technology, its future research and development directions may include improving drug formulations, enhancing bioavailability, reducing side effects, and other aspects. At the same time, it can also explore its combined application with other drugs to further improve the lipid-lowering effect and the efficacy of treating cardiovascular diseases. With the acceleration of globalization and the continuous development of international trade, the market for such lipid-lowering drugs will continue to expand. In the future, its manufacturing enterprises can actively explore international markets and enhance the international competitiveness of their products.
Lovastatin, a pioneering statin, exemplifies the transition from single-target drugs to multifunctional therapeutics. While its role in cardiovascular prevention remains paramount, emerging research highlights its potential in neurology, oncology, and infectious diseases.
Hot Tags: lovastatin cas 75330-75-5, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Tetracaine hydrochloride powder, 4 4 Diaminodiphenylsulfone CAS 80 08 0, IPTG reagent, Best Phenibut powder, pontocaine, lidocaine hydrochloride powder